A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Friday, 23 March 2012

New book on the way

Last week The SPC Blog posted some news from Poland, kindly sent in by Katarzyna Zbierska (Partner, Legal Counsellor, Kochański Zięba Rąpała i Partnerzy, Warsaw).

Katarzyna has also sent us a link to her book, Application and Importance of Supplementary Protection Certificates in the European Union, which will be published in Aachen, Germany, next month by Shaker Verlag. Katarzyna's book is based on her Ph.D. thesis, which she completed at the University of Augsburg last May under the supervision of someone who is no stranger to this blog, Professor Dr Ulrich M. Gassner. The book's web page is here (though you might get hijacked on the way to that page by the front page of the publisher's search service. According to the Abstract:
"The book focuses on supplementary protection certificates for medicinal products (SPC) created on the basis of the Council Regulation (EEC) no. 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (currently Regulation (EC) no. 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products). 
Since an SPC extends patent protection for a product, it provides an important advantage to innovative pharmaceutical companies in the European Union. The author discusses in detail various aspects of the legal mechanism of an SPC. She also presents similar legal concept in the USA as a benchmark for comparison of the European solution. The publication challenges the question of the importance and impact of an SPC on the European pharmaceutical market, among others, from a competition law perspective, as well as the role of an SPC in the context of other legal instruments available, such as market exclusivity and data exclusivity. This is particularly important as the current circumstances on the European pharmaceutical market differ much from those when the legal regime of the SPC was adopted. 
The publication also elaborates on the shortfalls of the current SPC system and identifies those areas which require amendments to address issues resulting from the rapidly changing situation on the pharmaceutical market in the European Union".

No comments: